Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2025 08:00 ET | Source: OncoC4, Inc.

OncoC4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation CTLA-4 Antibody Gotistobart Monotherapy Being Co-Developed with BioNTech in NSCLC at the IASLC 2025 World Conference on Lung Cancer

PRESERVE-003 is evaluating gotistobart vs. docetaxel in patients with squamous non-small cell lung cancer (sqNSCLC) who have progressed on chemotherapy and immune checkpoint therapies Pivotal Stage...
August 18, 2025 08:00 ET | Source: OncoC4, Inc.

OncoC4 Strengthens Leadership Team with Appointment of Shiniu Wei as Chief Financial Officer

ROCKVILLE, Md., Aug. 18, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today announced the appointment of Shiniu Wei as Chief...
July 28, 2025 08:00 ET | Source: OncoC4, Inc.

OncoC4 Announces New Preclinical Data Highlighting ONC-841, a Novel SIGLEC 10 Antibody, as a Potential New Class of Therapeutics for Alzheimer’s Disease

SIGLEC 10 identified as a genetic driver for amyloid plaque formation in mice ONC-841 blockade reduced amyloid plaques, normalized microglia function, and improved memory in preclinical...
July 22, 2025 07:00 ET | Source: OncoC4, Inc.

OncoC4 Doses First Patient with Potential Best-in-Class PD-1/VEGF Bispecific Antibody AI-081 in Phase 2 Portion of BIPAVE-001 Trial for Advanced Solid Tumors in US

ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer today announced the first patient has been dosed in the...
July 15, 2025 08:00 ET | Source: OncoC4, Inc.

OncoC4 to Present at the 2025 Orphan Drug Summit on Strategies to Eliminate Anti-Drug Antibodies in Orphan Therapies

ROCKVILLE, Md., July 15, 2025 (GLOBE NEWSWIRE) -- OncoC4, Inc., a late-stage biopharmaceutical company developing novel medicines for cancer, today announced it will present at the upcoming 2025...
April 16, 2025 08:00 ET | Source: OncoC4, Inc.

OncoC4 Selected to Present at the 2025 AACR Meeting's Showcase Session

Oral presentation will feature AI-081, a potentially best-in-class PD-1/VEGF bispecific antibody and ONC-841, a first-in-class anti-Siglec-10 antibody Initial clinical data for both AI-081 and...
December 02, 2024 08:00 ET | Source: OncoC4, Inc.

OncoC4 Announces FDA Clearance of IND Application for Potential Best-in-Class PD-1/VEGF Bispecific AI-081 in Advanced Solid Tumors

AI-081 is a differentiated bispecific antibody with robust cooperative interactions between PD1 and VEGF Dosing of first patient in BIPAVE-001 Phase 1/2 trial expected in Q1 2025 ROCKVILLE, Md.,...
September 25, 2024 07:00 ET | Source: OncoC4, Inc.

OncoC4 and AcroImmune Announce Merger

Merger expands OncoC4’s wholly owned immunotherapy pipeline and establishes in-house clinical manufacturing capabilities Adds IND-ready AI-081, a PD-1/VEGF bispecific antibody with best-in-class...
September 04, 2024 08:00 ET | Source: OncoC4, Inc.

OncoC4 Announces First Patient Dosed in Phase 1 Trial for Novel SIGLEC10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors

ONC-841 is a potential first-in-class SIGLEC10 antibody with broad application in oncology Designed to break tumor evasion of the immune system, ONC-841 can rejuvenate anti-tumor T cells, NK cells...
April 23, 2024 08:00 ET | Source: OncoC4, Inc.

OncoC4 Announces FDA Clearance of IND Application for Novel SIGLEC 10 Immune Checkpoint Inhibitor ONC-841 for Solid Tumors

ONC-841 is a potential first-in-class SIGLEC 10 antibody designed to block an innate and potentially adaptive immune checkpoint and prevent cancer evasion of immune cellsAnti-tumor T cells, NK cells...